Regeneron leaps on positive FDA review of wet AMD drug
This article was originally published in Scrip
Executive Summary
US regulators had no qualms about the safety and efficacy of Regeneron Pharmaceuticals' Eylea (aflibercept), also known as VEGF Trap EYE, in treating patients with neovascular (wet) age-related macular degeneration (AMD), the US FDA revealed in briefing documents on 15 June ahead of an advisory panel's review.